MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus is a paper indexed in ScholarIQ from OpenAlex.
How many citations does MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus have?
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus has 102 citations in the OpenAlex counts ScholarIQ stores.
When was MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus published?
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus has 2022 year in the ScholarIQ index.
What is the open-access status of MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus?
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus has bronze oa status in the ScholarIQ index.
What is the DOI of MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus?
The DOI for MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus is on the source record.
What is the PMID of MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus?
The PMID for MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus is on the source record.
What is the OpenAlex record for MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus?
The OpenAlex for MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus is on the source record.